CDE Catalog

***Please contact the NINDS CDE Team (NINDSCDE@emmes.com) if you encounter any search difficulties.***

The CDE Catalog is a directory of the available NINDS CDEs. Users can search the Catalog to isolate a subset of the CDEs (e.g., all stroke-specific CDEs, etc.), and to view and download details about the CDEs.

Select any filter below to search the CDE Catalog.

For best results, clear form between searches. In addition, when specifying NeuroRehab, Sport-Related Concussion (SRC) or Traumatic Brain Injury (TBI) as the Disease, please select a Subdisease as well.

NeuroRehab Comprehensive includes all NeuroRehab CDE recommendations. NeuroRehab General includes all NeuroRehab CDE recommendations that are not disease specific. All other NeuroRehab Subdiseases include recommendations specific to existing NINDS CDE project disorders.

Choose your Time Frame for your SRC study (Acute (time of injury until 72 hours), Subacute (after 72 hours to 3 months), and Persistent/Chronic (3 months and greater post-concussion) or Comprehensive if your study falls across the study time frames.

Choose your type of TBI study (Acute Hospitalized, Concussion/Mild TBI, Moderate/Severe TBI: Rehabilitation, or Epidemiology) or Comprehensive if your study falls outside of the study types or incorporates aspects of more than one type of study.

Search Form

Displaying 226 - 250 of 57861
Operations
Selected 25 rows in this page.  
The search results below can be downloaded by clicking the checkboxes on the far left side of the table. Select the header checkbox to select all CDEs listed on the first page. Then choose CDE Detailed Report from the Choose an operation dropdown menu.
CDE ID CDE Name Definition Classification CRF Name Copyrighted or trademarked Disease Name Subdisease Name
C53105 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Form A Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of Form A of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Subacute
C53121 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Form B Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of Form B of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Comprehensive
C53121 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Form B Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of Form B of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Acute
C53121 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Form B Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of Form B of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Persistent/Chronic
C53121 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Form B Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of Form B of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Subacute
C53146 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Comprehensive
C53146 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Acute
C53146 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Persistent/Chronic
C53146 Test of Word Reading Efficiency-Second Edition (TOWRE-2) - Sight Word Efficiency (SWE) test age equivalent category

Age Equivalent category of the Sight Word Efficiency (SWE) test, as part of the Test of Word Reading Efficiency-Second Edition (TOWRE-2)

Exploratory Test of Word Reading Efficiency 2nd Edition (TOWRE-2) Sport-Related Concussion Subacute
C54992 Cocaine exposure age start value

Age in years at which the subject/participant began exposure to cocaine

Supplemental Prior and Concomitant Medications Stroke Stroke
C54992 Cocaine exposure age start value

Age in years at which the subject/participant began exposure to cocaine

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54983 Medication anticoagulant current former take age start value

Age in years at which the subject/participant began taking the selected former or current anticoagulant medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54956 Medication antihypertensive current former take age start value

Age in years at which the subject/participant began taking the selected former or current antihypertensive medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54961 Medication antiplatelet current former take age start value

Age in years at which the subject/participant began taking the selected former or current antiplatelet medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C55001 Medication immunosuppressant current former take age start value

Age in years at which the subject/participant began taking the selected former or current immunosuppressant medication

Exploratory Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54988 Stimulant current former use age start value

Age in years at which the subject/participant began taking the selected former or current stimulant

Supplemental Prior and Concomitant Medications Stroke Stroke
C54988 Stimulant current former use age start value

Age in years at which the subject/participant began taking the selected former or current stimulant

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54978 Hormone therapy current former receive age start value

Age in years at which the subject/participant began taking the specified former or current hormone therapy

Exploratory Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54974 Non-steroidal anti-inflammatory drug current former take age start value

Age in years at which the subject/participant began taking the specified former or current non-steroidal anti-inflammatory drug (NSAID)

Exploratory Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54996 Potency enhancing drug current former use age start value

Age in years at which the subject/participant began taking the specified former or current potency-enhancing drug

Exploratory Prior and Concomitant Medications Stroke Stroke
C54996 Potency enhancing drug current former use age start value

Age in years at which the subject/participant began taking the specified former or current potency-enhancing drug

Exploratory Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54965 Medication statin current former take age start value

Age in years at which the subject/participant began taking the specified former or current statin medication

Exploratory Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54984 Medication anticoagulant former take age end value

Age in years at which the subject/participant stopped taking the selected former anticoagulant medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54957 Medication antihypertensive former take age end value

Age in years at which the subject/participant stopped taking the selected former antihypertensive medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
C54962 Medication antiplatelet former take age end value

Age in years at which the subject/participant stopped taking the selected former antiplatelet medication

Supplemental Concomitant Medications Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage Unruptured Cerebral Aneurysms and Subarachnoid Hemorrhage
Displaying 226 - 250 of 57861

The NINDS CDE Team does not post proprietary instruments/scales recommended by the CDE Working Groups on this website. This includes, but is not limited to, copyrighted or trademarked instruments/scales. Information about recommended instruments can be found in the Notice of Copyright (NOC) documents under ‘CRF Module/Guideline’ on each disorder’s data standards page. For any questions regarding these instruments/scales please contact the corresponding owner/author. The NINDS CDE Team is not responsible for the availability or content of these external sites, nor does the NINDS CDE Team endorse, warrant or guarantee the products, services or information described or offered at these other internet sites.